EUVIMEDEUVIMED entdecken
Multizentrische Studie

Prognosis Associated with Complete Pathological Response Following Neoadjuvant Treatment for PancreaTic AdenOcarciNOma in the FOFLIRINOX Era: the Multicenter TONO Study

Pietro Addeo, Milena Muzzolini, Christophe Laurent, Bruno Heyd, Alain Sauvanet, Jonathan Garnier, Marie Sophie Alfano, Sebastien Gaujoux, Charles De Ponthaud, Ugo Marchese, Doris Da Silva, Emmanuel Buc und 29 weitere

Annals of Surgical Oncology · 2025

DOI: 10.1245/s10434-024-16735-2 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Annals of Surgical Oncology, 2025. Verfasst von Pietro Addeo und 40 weiteren Autor:innen. Beteiligte Einrichtung: Hepato-Pancreato-Biliary Surgery and Liver Transplantation, Pôle des Pathologies Digestives et Hépatiques, Hôpital de Hautepierre-Hôpitaux Universita…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Neoadjuvant Therapy, Antineoplastic Combined Chemotherapy Protocols, Adenocarcinoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The use of multiagent FOLFIRINOX chemotherapy for pancreatic adenocarcinoma in a neoadjuvant setting has been associated with an increased rate of complete pathological response (CPR) after surgery. This study investigated the long-term outcomes of patients with CPR in a multicenter setting to identify prognostic factors for overall survival (OS) and recurrence-free survival (RFS). METHODS: This retrospective cohort study examined biopsy-proven pancreatic adenocarcinomas with CPR after neoadjuvant chemotherapy or chemoradiotherapy and surgery, between January 2006 and December 2023 across 22 French and 2 Belgian centers. Cox analyses were used to identify prognostic factors of OS and RFS. RESULTS: There were 101 patients with CPR after chemotherapy (n = 58, 57.4%) and chemoradiotherapy (n = 43, 42.6%) followed by surgery. Neoadjuvant FOLFIRINOX was used in 90% of patients. The median OS after surgery was 177 months (95% confidence interval (CI) 58.9-177 months) with 1-, 3-, 5-, and 10-year OS rates of 93%, 75%, 63%, and 51%, respectively. The median RFS was 67.8 months (95% CI:34.4-NR) with 1-, 3-, 5-, and 10-year RFS rates of 83%, 58%, 54%, and 49%, respectively. The multivariate Cox analysis of OS and RFS showed that preoperative radiotherapy was an independent negative prognostic factor for OS (hazard ratio (HR) 2.51; 95% CI 1.00-6.30; p = 0.03) and RFS (HR 2.62; 95% CI 1.27-5.41; p = 0.009). CONCLUSIONS: Complete pathologic response after neoadjuvant treatment is associated with remarkable long-term survival that is usually not seen after the resection of pancreatic adenocarcinomas. One-third of the patients still experienced disease recurrence, which was more common in those receiving preoperative chemoradiotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsNeoadjuvant TherapyAntineoplastic Combined Chemotherapy ProtocolsAdenocarcinomaNeoplasm Recurrence, LocalHumansMaleFemaleRetrospective StudiesMiddle AgedPrognosisAgedSurvival RateFluorouracilOxaliplatinIrinotecanFollow-Up StudiesLeucovorinAdult

Stichwörter der Autor:innen

Complete pathologic responseFOLFIRINOXNeoadjuvant chemotherapyPancreatic adenocarcinomaRadiotherapy

Substanzen

FluorouracilOxaliplatinIrinotecanLeucovorinfolfirinox

Autor:innen und Institutionen

  • Hepato-Pancreato-Biliary Surgery and Liver Transplantation, Pôle des Pathologies Digestives et Hépatiques, Hôpital de Hautepierre-Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, Strasbourg, France. piet…
  • Department of HBP Surgery, AP-HP, Hôpital Beaujon, University of Paris, Clichy, France.
  • Department of Digestive Surgery, Centre Magellan-CHU Bordeaux, Bordeaux, France.
  • Department of Digestive Surgical Oncology, University Hospital of Besançon, Besançon, France.
  • Department of Oncological Surgery, Institut Paoli Calmettes, Marseille University, Marseille, France.
  • Department of Hepato-Biliary and Pancreatic Surgery and Liver Transplantation, AP-HP, Pitié-Salpêtrière Hospital, Paris, France.

Zitieren

APA

Addeo, P., Muzzolini, M., Laurent, C., Heyd, B., Sauvanet, A., Garnier, J., Alfano, M. S., Gaujoux, S., De Ponthaud, C., Marchese, U., Da Silva, D., Buc, E., Souche, R., Fabre, J. M., Colombo, P. E., Ferre, L., Foguenne, M., Hubert, C., El Amrani, M., …, & Bachellier, P. (2025). Prognosis Associated with Complete Pathological Response Following Neoadjuvant Treatment for PancreaTic AdenOcarciNOma in the FOFLIRINOX Era: the Multicenter TONO Study. Annals of Surgical Oncology. https://doi.org/10.1245/s10434-024-16735-2

Vancouver

Addeo P, Muzzolini M, Laurent C, Heyd B, Sauvanet A, Garnier J, et al. Prognosis Associated with Complete Pathological Response Following Neoadjuvant Treatment for PancreaTic AdenOcarciNOma in the FOFLIRINOX Era: the Multicenter TONO Study. Annals of Surgical Oncology. 2025. doi:10.1245/s10434-024-16735-2

BibTeX
@article{Addeo2025,
  author = {Addeo, Pietro and Muzzolini, Milena and Laurent, Christophe and Heyd, Bruno and Sauvanet, Alain and Garnier, Jonathan and Alfano, Marie Sophie and Gaujoux, Sebastien and De Ponthaud, Charles and Marchese, Ugo and Da Silva, Doris and Buc, Emmanuel and Souche, Regis and Fabre, Jean Michel and Colombo, Pierre-Emanuel and Ferre, Lorenzo and Foguenne, Maxime and Hubert, Catherine and El Amrani, Mehdi and Truant, Stephanie and Schwartz, Lilian and Regenet, Nicolas and Dupre, Aurelien and Brustia, Raffaele and Cherif, Rim and Navez, Julie and Darnis, Benjamin and Facy, Olivier and Grellet, Robin and Piessen, Guillaume and Veziant, Julie and Rhaiem, Rami and Kianmanesh, Reza and Fernandez-De-Sevilla, Elena and Gelli, Maximiliano and Taibi, Abdelkader and Georges, Pauline and Mabrut, Jean Yves and Lesurtel, Mickael and Doussot, Alexandre and Bachellier, Philippe},
  title = {Prognosis Associated with Complete Pathological Response Following Neoadjuvant Treatment for PancreaTic AdenOcarciNOma in the FOFLIRINOX Era: the Multicenter TONO Study},
  journal = {Annals of Surgical Oncology},
  year = {2025},
  doi = {10.1245/s10434-024-16735-2}
}
Kostenlos starten →